For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Ribozyme Pharmaceuticals, Incorporated

USPTO Granted Patents = 110

% Expired Patents = 1.8

EPO Patents = 1

Forward Citations = 4,023

Loading Chart...

Loading Chart...

56 inventors (with patents filed for the assignee):

Leonid Beigelman (41 out of 227 patents)

Kenneth G Draper (33 out of 43 patents)

James A McSwiggen (30 out of 99 patents)

4. Nassim Usman (25 out of 32 patents)

5. Jasenka Matulic-Adamic (20 out of 29 patents)

6. Dan T Stinchcomb (19 out of 57 patents)

7. James D Thompson (16 out of 19 patents)

8. Alex Karpeisky (15 out of 17 patents)

9. Alexander Karpeisky (14 out of 28 patents)

10. Francine E Wincott (12 out of 17 patents)

11. David Sweedler (9 out of 16 patents)

12. Alex B Burgin (7 out of 8 patents)

13. Sean M Sullivan (7 out of 10 patents)

14. Thale Jarvis (6 out of 22 patents)

15. Laurent Bellon (6 out of 8 patents)

Core Competencies:

Nucleic Acid Catalysts

Enzymatic Nucleic Acids

Therapeutic RNAs

Nucleoside Analogues

RNA Polymerase III

Ribozymes

RNA Cleavage

Viral Inhibition

Gene Expression

Nucleotide Modifications

RNA Synthesis

Disease Treatment

110 patents: Sort by Forward Citations

1. 6602858 - Nucleic acid catalysts comprising L-nucleotide analogs (2003-08-05),

2. 6586238 - Enzymatic nucleic acids containing 5′-and or 3′-cap structures (2003-07-01),

3. 6555668 - Non-nucleotide containing enzymatic nucleic acid (2003-04-29),

4. 6548657 - Method for screening nucleic acid catalysts (2003-04-15),

5. 6544755 - Method and reagent for treatment of diseases by expression of the c-Myc gene (2003-04-08),

6. 6528640 - Synthetic ribonucleic acids with RNAse activity (2003-03-04),

7. 6528639 - Base-modified enzymatic nucleic acid (2003-03-04),

8. 6509460 - Nucleoside triphosphates and their incorporation into oligonucleotides (2003-01-21),

9. 6506888 - 2′-O-amino-containing nucleoside analogs and polynucleotides (2003-01-14),

10. 6492512 - Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression (2002-12-10),

11. 6489465 - Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides (2002-12-03),

12. 6482932 - Nucleoside triphosphates and their incorporation into oligonucleotides (2002-11-19),

13. 6469158 - Synthesis, deprotection, analysis and purification of RNA and ribozymes (2002-10-22),

14. 6451540 - 2′-O-alkylthioalkyl and 2′-C-alkythioalkyl containing nucleic acids (2002-09-17),

15. 6448009 - Method for target site selection and discovery (2002-09-10),

Ribozyme Pharmaceuticals, incorporated is a leading biopharmaceutical company specialized in developing novel RNA-based therapeutics. We leverage the unique catalytic properties of ribozymes to create innovative drugs for a wide range of diseases, including genetic disorders, cancer, and viral infections. Our dedicated team of scientists and researchers work tirelessly to discover and optimize ribozyme-based therapies that have the potential to revolutionize healthcare. Visit our website to learn more about our cutting-edge developments and commitment to improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

110 Patents

#11 in Boulder, CO

#69 in Colorado

#3,472 in US

#7,150 in the World

Boulder, CO, United States of America

Ribozyme Pharmaceuticals, Incorporated

Forward Citations = 4,023

56 inventors:

Leonid Beigelman (41 out of 227 patents)

Kenneth G Draper (33 out of 43 patents)

James A McSwiggen (30 out of 99 patents)

4. Nassim Usman (25 out of 32 patents)

5. Jasenka Matulic-Adamic (20 out of 29 patents)

Please report any incorrect information to [email protected]

Loading…